Supriya Krishna

Supriya Krishna

Auto-generated profile, based on publicly available information

Supriya Krishna

Muscle Research Unit, Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité – Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
OGOskar Gustafsson
Oskar Gustafsson
SKSupriya Krishna
Supriya Krishna
SBSophia Borate
Sophia Borate
MGMarziyeh Ghaeidamini
Marziyeh Ghaeidamini
XLXiuming Liang
Xiuming Liang
OGOskar Gustafsson
Oskar Gustafsson
Efficient delivery of the CRISPR/Cas9 system and its larger derivatives, base editors, and prime editors remain a significant challenge, particularly in tissue-specific stem cells and induced pluripotent stem cells (iPSCs). This study optimized a novel family of cell-penetrating peptides, hPep, to deliver gene-editing ribonucleoproteins. The hPep-based nanoparticles enable highly efficient and biocompatible delivery of Cre recombinase, Cas9, base-, and prime editors. Using base editors, robust and nearly complete genome editing was achieved in the human cells: HEK293T (96%), iPSCs (74%), and muscle stem cells (80%). This strategy opens promising avenues for ex vivo and, potentially, in vivo applications. Incorporating silica particles enhanced the system’s versatility, facilitating cargo-agnostic delivery. Notably, the nanoparticles can be synthesized quickly on a benchtop and stored as lyophilized powder without compromising functionality. This represents a significant advancement in the feasibility and scalability of gene-editing delivery technologies.